About
Kenneth I. Moch is a veteran life sciences executive who has led multiple biotech and medical-technology companies, including Chimerix, Cognition Therapeutics, Alteon, and BioMedical Enterprises. He has been involved in founding, financing, and leading companies developing therapies in Alzheimer's disease, antivirals, biodefense, cardiovascular aging, diabetes, stem-cell transplantation, oncology, and antifungal medicine. Public sources also place him in biotech policy and ethics leadership through the Biotechnology Innovation Organization and NYU Langone's compassionate-use working group.
Areas of interest
biotechlife sciencesdrug developmentalzheimer's diseaseneuroscienceantiviralsbiodefensecardiovascular agingdiabetescord blood stem cell transplantationoncologyantifungal therapeuticsbioethicshealthcare finance